BSPM
Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operating Income of $16 - $17 Million Excluding Non-cash Charges
XIANYANG, China, Feb 25, 2010 /PRNewswire via COMTEX/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced preliminary unaudited revenue between $52 to $54 million for its fiscal year ended December 31, 2009.
Biostar expects to report gross margin for 2009 of approximately 71%, an increase of 1200 basis-points compared to 59% in 2008. Management anticipates unaudited operating income, excluding non-cash charges, of approximately $16 to $17 million, an increase of 100% to 113% compared to $8 million in 2008.
"2009 was a very positive year for Biostar. The success of our marketing strategy for our Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing Capsule") helped us achieve the best financial results in our company's history for 2009," commented Chairman Mr. Ronghua Wang. "We also experienced growing sales for our other products as we penetrated China's rural markets. For 2010, our focus is on driving higher sales volumes of Xin Aoxing Capsule in the existing and new provinces we serve, introducing new products, and leveraging our rural network sale strategy to generate incremental revenue growth," added Mr. Wang.
Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operating Income of $16 - $17 Million Excluding Non-cash Charges
XIANYANG, China, Feb 25, 2010 /PRNewswire via COMTEX/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced preliminary unaudited revenue between $52 to $54 million for its fiscal year ended December 31, 2009.
Biostar expects to report gross margin for 2009 of approximately 71%, an increase of 1200 basis-points compared to 59% in 2008. Management anticipates unaudited operating income, excluding non-cash charges, of approximately $16 to $17 million, an increase of 100% to 113% compared to $8 million in 2008.
"2009 was a very positive year for Biostar. The success of our marketing strategy for our Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing Capsule") helped us achieve the best financial results in our company's history for 2009," commented Chairman Mr. Ronghua Wang. "We also experienced growing sales for our other products as we penetrated China's rural markets. For 2010, our focus is on driving higher sales volumes of Xin Aoxing Capsule in the existing and new provinces we serve, introducing new products, and leveraging our rural network sale strategy to generate incremental revenue growth," added Mr. Wang.
Ehh, RINO is nothing special ... barely a double even from these beat down prices. Then again, with the short volume pushing it down this far, I'm sure they're looking to cover soon as the damage has already been done. It'll probably pop back to the $22 level quick, so it could be a nice quick flip.
I'd go with something like CCME or DJSP if you're looking for a fully-listed company and want to make some serious ROI.
JADA on the other hand is a steal down here. I'm expecting solid numbers again next Q and I dont see it staying below .60 for long after they report or possibly even before they report. It definitely has strong support at .33-.38 ... you get the green light to load up here. Will likely gravitate back towards $1 over the next few months.
ABWTQ wish I knew what was wrong with this Q ... but I dont. I'm still holding a large position with an avg price of .115 now.
NEWN ... waiting on Q4 numbers to add as there might be some weakness. 2010 will be a great year for NEWN though, and if there is weakness on Q4 numbers, it will be a great buying opportunity. Anything under $8 is a steal.
SGZH -- when Q4 numbers come out, it will likely be hard to get under $10, probably even under $12. Patience always pays off, Wall St is almost always slow to react. Tick Tock.
Yeah, we've got a nice bowl formation on the S&P now (Cup and Handle -- BULLISH). Looks like big money is buying the dip (check the OBV for SPY) ... get your rally caps back out. Correction is over and the market has digested sovereign debt / Euro concerns imo. Dollar correlation is starting to not matter as much to the market, but is still affecting commodities.
Lets see where we finish, but I see a few China names about to go green and already have a few that are.
Fundamentals are starting to matter again, and once they matter entirely, we'll have a good ol' fashion stock picker's market and the RX Forum will be one step ahead of those stock pickers. GLTA
CCME -- March will be CCME's month.
CCME will be presenting at two huge investor conferences in March, not to mention they will be reporting earnings towards the middle of March. They have not given a specific date for earnings, but I will update the board as soon as one is given. I believe they will also be hosting a Con Call, but this has not been confirmed.
CCME is presenting at the Rodman Conference on March 8th at 3:30PM.
http://www.meetmax.com/sched/event_5281/~public/conference_presentations.html?event_id=5281
CCME is also presenting at the Roth Capital Partners 22nd Annual OC Growth Stock Conference on March 16 at 3:30p PST.
http://www.roth.com/main/page.aspx?PageID=7229
Believe it or not, stocks usually move big if investors / venture capitalists are impressed with what the company has to say about its future. TSTC made a nice 15% move last year when they presented at the Brean Murray Conference. I fully expect this to open investors' eyes, but we also have the earnings catalyst in March as well.
All I can say is, if you dont own CCME in March, you will likely regret it. March will show you why the early bird gets the worm, and how being early can cause frustration, but you need to stick with your guns ... Wall St is always slow to react.
Here's the full list of companies that will be presenting at the Roth Capital conference: http://www.uschinastocks.com/2010/0...g-at-roth-capital-22nd-annual-conference.html
There are several others that I've mentioned here that will be presenting.
CCME will be presenting at two huge investor conferences in March, not to mention they will be reporting earnings towards the middle of March. They have not given a specific date for earnings, but I will update the board as soon as one is given. I believe they will also be hosting a Con Call, but this has not been confirmed.
CCME is presenting at the Rodman Conference on March 8th at 3:30PM.
http://www.meetmax.com/sched/event_5281/~public/conference_presentations.html?event_id=5281
CCME is also presenting at the Roth Capital Partners 22nd Annual OC Growth Stock Conference on March 16 at 3:30p PST.
http://www.roth.com/main/page.aspx?PageID=7229
Believe it or not, stocks usually move big if investors / venture capitalists are impressed with what the company has to say about its future. TSTC made a nice 15% move last year when they presented at the Brean Murray Conference. I fully expect this to open investors' eyes, but we also have the earnings catalyst in March as well.
All I can say is, if you dont own CCME in March, you will likely regret it. March will show you why the early bird gets the worm, and how being early can cause frustration, but you need to stick with your guns ... Wall St is always slow to react.
Here's the full list of companies that will be presenting at the Roth Capital conference: http://www.uschinastocks.com/2010/0...g-at-roth-capital-22nd-annual-conference.html
There are several others that I've mentioned here that will be presenting.
BSPM
<TABLE style="TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%"><TBODY><TR><TD align=middle>Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 Million and Net Income $16.2 to $17 Million
</TD></TR><TR><TD>Biostar Pharmaceuticals, Inc. (BULLETIN BOARD: BSPM) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), and a variety of pharmaceutical products and medical nutrients, today announced revenue and net income guidance for the fiscal year ending December 31, 2010.
Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to 70% of revenues during 2010.
The net income forecast does not include non-cash expenses associated with any compensation plans. The Company's guidance does not include any contribution from future acquisitions or pending acquisitions previously announced by the Company or otherwise. Management will continue to evaluate its business outlook as necessary and communicate any changes on a quarterly basis or when appropriate.
The growth strategy for 2010 is supported by the following initiatives: (1) the introduction of Xin Aoxing into three new markets including Chongqing, Jiangxi and Jiangsu, which, including the Company's previously announced launch in Tianjin, Beijing and Shanghai in January 2010, will bring the total number of markets served by the Company's direct sales offices to 21; (2) to continue increasing the Company's presence in rural markets with a goal of reaching 10,000 sales outlets by the end of 2010; and (3) further product diversification through research and development and new product launches upon successful clinical trials and permitting procedures.
"We are optimistic about our prospects in 2010," commented Chairman Mr. Ronghua Wang. "We successfully established a solid foundation for future growth during 2009 which will greatly benefit our growth during 2010." About Biostar Pharmaceuticals, Inc.
</TD></TR></TBODY></TABLE>
<TABLE style="TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%"><TBODY><TR><TD align=middle>Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 Million and Net Income $16.2 to $17 Million
</TD></TR><TR><TD>Biostar Pharmaceuticals, Inc. (BULLETIN BOARD: BSPM) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), and a variety of pharmaceutical products and medical nutrients, today announced revenue and net income guidance for the fiscal year ending December 31, 2010.
Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to 70% of revenues during 2010.
The net income forecast does not include non-cash expenses associated with any compensation plans. The Company's guidance does not include any contribution from future acquisitions or pending acquisitions previously announced by the Company or otherwise. Management will continue to evaluate its business outlook as necessary and communicate any changes on a quarterly basis or when appropriate.
The growth strategy for 2010 is supported by the following initiatives: (1) the introduction of Xin Aoxing into three new markets including Chongqing, Jiangxi and Jiangsu, which, including the Company's previously announced launch in Tianjin, Beijing and Shanghai in January 2010, will bring the total number of markets served by the Company's direct sales offices to 21; (2) to continue increasing the Company's presence in rural markets with a goal of reaching 10,000 sales outlets by the end of 2010; and (3) further product diversification through research and development and new product launches upon successful clinical trials and permitting procedures.
"We are optimistic about our prospects in 2010," commented Chairman Mr. Ronghua Wang. "We successfully established a solid foundation for future growth during 2009 which will greatly benefit our growth during 2010." About Biostar Pharmaceuticals, Inc.
</TD></TR></TBODY></TABLE>
